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Abstract
Organic chemists and metabolic engineers use largely orthogonal technologies to construct 
essential small molecules like pharmaceuticals and commodity chemicals. While chemists have 
leveraged the unique capabilities of biological catalysts for small molecule production, metabolic 
engineers have not likewise integrated reactions from organic synthesis with the metabolism of 
living organisms. Here we report a method for alkene hydrogenation that utilizes a palladium 
catalyst and hydrogen gas generated directly by a living microorganism. This biocompatible 
transformation, which requires both catalyst and microbe and can be used on a preparative scale, 
represents a new strategy for chemical synthesis that combines organic chemistry and metabolic 
engineering.
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Two scientific disciplines, organic chemistry and metabolic engineering, endeavor to 
produce small molecules using very different techniques.[1,2] Synthetic organic chemists 
largely employ non-biological catalysts and reagents to manipulate molecules in multi-step 
processes, while metabolic engineers harness the reactivity of enzymatic catalysts in the 
context of living organisms to produce molecules directly from fermentations.[3,4] While 
organic chemists have been increasingly utilizing enzymes in synthetic efforts[5] such as the 
industrial-scale synthesis of the diabetes drug sitagliptin (Januvia®),[6] efforts to synthesize 
molecules by incorporating reactions from organic synthesis into biological systems have 
lagged behind. We envision achieving this goal using biocompatible chemistry: non-
enzymatic transformations that directly interface with the metabolism of living organisms, 
modifying small molecule metabolites as they are produced and augmenting native 
biochemistry (Figure 1A).[7]
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Perhaps the largest obstacle faced in this endeavor is the discordance between the conditions 
typically required to support life and those often used in organic synthesis (non-aqueous 
solvents, extreme temperatures, reactive intermediates). For example, the problem of mutual 
catalyst inactivation can at times complicate efforts to combine transition metal catalysts 
with purified enzymes in vitro.[8] Additional challenges include the chemical complexity of 
the cellular and extracellular environments, the typically low concentrations of metabolites, 
and the potential difficulties associated with accessing intracellular substrates. 
Encouragingly, similar problems have been surmounted in developing bioorthogonal 
reactions, which are used to study biological phenomena in living cells and organisms 
without altering underlying cellular processes.[9] While such transformations illustrate that 
non-enzymatic chemistry can proceed in the presence of living systems,[10] their application 
toward small molecule synthesis has been underexplored.
We identified hydrogen gas[11] as a target metabolite for an initial proof-of-concept reaction: 
a biocompatible alkene hydrogenation that would directly combine hydrogen generated by 
living bacteria with a transition metal catalyst and could be utilized for preparative scale 
synthesis (Figure 1B). This choice was motivated by previous reports suggesting transition 
metal-catalyzed hydrogenation was compatible with living cells. Specifically, unsaturated 
bacterial membrane lipids can be reduced with transition metal catalysts and added 
hydrogen gas.[12a] Bacterially produced hydrogen can also directly reduce organic dyes[12b] 
and ethylene[12c] on an analytical scale using superstoichiometric amounts of catalyst. 
Though these examples provided important precedent for the desired chemical reactivity, 
they did not imply or demonstrate synthetic utility (e.g. preparative scale, broad substrate 
scope). Beyond its potential use for chemical synthesis, we also envisioned using our 
hydrogenation to elucidate factors influencing the success of biocompatible reactions.
We began by investigating whether hydrogenation could take place in media complex 
enough to support the growth of E. coli, our intended source of hydrogen (Table 1). We 
incubated the water-soluble alkene caffeic acid (1a) with platinum(IV)oxide in two types of 
growth media under an atmosphere of hydrogen gas (Entries 1 and 2) and found that a 
defined minimal medium (M9 glucose) provided higher conversion than a complex medium 
(Luria-Bertani (LB) + 0.5% glucose). We then examined the impact of bacteria on these 
reactions by performing hydrogenations under an atmosphere of hydrogen gas in growth 
media containing E. coli DD-2 (optical density (OD)600 = 0.4). This engineered strain 
produces hydrogen from glucose via an inducible pathway consisting of a pyruvate 
ferredoxin oxidoreductase, a ferredoxin, and a [Fe-Fe] hydrogenase.[13] We observed little 
change in conversion with organisms in the reaction mixture (Entries 3 and 4). Finally, we 
incubated catalyst and substrate in the presence of E. coli DD-2 under a nitrogen 
atmosphere, relying on bacterial production of hydrogen gas (Entries 5 and 6, Figure 1C). 
We observed 15% conversion for the reaction run in M9 glucose, providing support for our 
general reaction design.
Our initial optimization efforts focused on varying growth medium and catalyst (Table 1, 
Tables S3–4). Based on the increased conversions observed for reactions performed with 
added hydrogen, we suspected that hydrogen production by E. coli DD-2 was limiting 
reaction efficiency. We tested various media additives and found that adding either iron or 
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casamino acids (Table S3) to minimal media improved conversion. The combination of both 
additives provided a further increase (Table 1, Entry 7). These components may boost 
hydrogen generation by increasing the amount of functional [Fe-Fe] hydrogenase.[14]
We screened a variety of heterogeneous hydrogenation catalysts using our improved 
reaction media. While most catalysts examined provided no reactivity (Table S4), the Royer 
palladium catalyst[15] (2.44% palladium on polyethyleneimine (PEI)/silica gel) proved 
uniquely effective.[16] Using this catalyst, we could double the concentration of substrate 
and reduce catalyst loading to 8 mol% without impacting conversion (Table 1, Entry 8). 
Further optimization experiments were carried out with a more challenging substrate (E)-3-
(3,4,5-trimethoxyphenyl)acrylic acid (1b) (Figure S2, Tables S5–S11). Ultimately, we 
identified conditions that were readily scaled to hydrogenate 9 mmol (1.6 g) of 1a (Table 1, 
Entry 9). The ease with which we could apply this transformation to larger scale reactions is 
notable, and may indicate that this general approach is suitable for preparative scale 
synthesis.
We used these optimal reaction conditions to evaluate functional group compatibility, as it 
was unclear to what extent the presence of living organisms would impact substrate scope. 
Overall, the hydrogenation displayed broad utility for preparative-scale reactions of water-
soluble alkenes (Figure 2). An alkyne substrate (1k) also underwent exhaustive 
hydrogenation to the corresponding alkane. Most notably, 2-hexenedioic acid (1x) and Z,Z-
muconic acid (1y) were converted to adipic acid, an important industrial chemical that is 
produced on a multimillion ton scale annually and has been a frequent but challenging target 
for metabolic engineering.[17] These results suggest that adipic acid could be obtained 
directly from fermentations by combining a biocompatible hydrogenation catalyst with 
organisms that produce hydrogen and an alkene such as 1y, which has already been 
generated via engineered microbes.[18]
Finally, we investigated how the biocompatible hydrogenation takes place and its impact on 
E. coli. A series of control experiments delineated the requirements for a successful reaction 
(Figure 3A, Table S12). We also quantified the hydrogen and formic acid produced in each 
reaction mixture, as both metabolites could potentially contribute to hydrogenation.[19] No 
reaction was observed in the absence of catalyst, confirming that E. coli cannot reduce 1a. 
The presence of E. coli was essential, indicating that the organisms contribute a key reaction 
component. The low conversions observed for the –IPTG control and a parental E. coli 
strain that cannot generate hydrogen support our hypothesis that hydrogen gas is the primary 
metabolite contributing to the transformation.[20] Finally, we assessed the importance of 
catalyst-cell contact by sequestering the E. coli in dialysis cassettes. Hydrogenation still 
occurs, albeit with lower conversion, indicating that physical interaction is not a requirement 
(Table S12, Entry 11). However, E. coli is known to adsorb onto PEI,[21] and increased 
catalyst-cell proximity via this mechanism could contribute to the Royer catalyst’s superior 
utility relative to other heterogeneous catalysts.
The application of non-enzymatic catalysts and reagents in metabolic engineering requires 
that they do not significantly impede host growth and metabolism. To ascertain whether the 
E. coli survive the hydrogenation, we performed serial dilutions and plate counts directly 
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from spent reaction mixtures, systematically omitting reaction components to assess 
biocompatibility (Figure 3B). Remarkably, we observed no significant difference in survival 
between reactions with and without catalyst. Together with the experiment exploring spatial 
separation, this result may indicate that the hydrogenation occurs outside of cells. Additional 
experiments to fully elucidate the factors influencing catalyst activity and compatibility will 
be the focus of future research.
In summary, this work demonstrates that the metabolic output of living microbes and a 
biocompatible non-enzymatic transformation may be combined to enable preparative scale 
chemical synthesis. Although this methodology cannot yet match the efficiency of more 
established approaches,[22,23] this advance represents a crucial first step in merging the 
fields of organic chemistry and metabolic engineering and complements parallel efforts to 
engineer non-biological reactivity into enzyme scaffolds.[24] Ultimately, full integration of 
biocompatible reactions with cellular metabolism could provide access to chemical 
reactivity that would otherwise be out of reach in a cellular setting and molecules that could 
not be made using biological chemistry alone.
Experimental Section
General materials and methods, hydrogenation catalyst synthesis and analysis, reaction 
discovery and optimization, control reactions and metabolite analyses, assessment of 
catalyst toxicity, and compound characterization data are all described in the Supporting 
Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Biocompatible chemistry enables the integration of non-enzymatic reactions with microbial 
metabolism. a) Biocompatible chemistry represents a distinct approach for synthesis that 
employs chemical tools in a biological environment. b) Design of a biocompatible alkene 
hydrogenation that uses hydrogen gas produced directly by microbial metabolism for 
synthesis.
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Functional group tolerance of the biocompatible hydrogenation. Values shown are isolated 
yields for preparative scale reactions (5 mM substrate concentration with 8 mol% Royer 
catalyst in 90 mL of growth medium under an atmosphere of nitrogen in serum bottles 
shaken at 190 rpm) unless indicated otherwise.x Isolated yield for a preparative scale 
reaction run with 16 mol% Royer catalyst.y The reaction was run with 2.5 mM substrate.
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Requirements of the biocompatible hydrogenation and its effect on E.oli. a) Control 
experiments and metabolite analyses. Reactions were run with 5 mM of substrate 1a and 8 
mol% Royer catalyst in 7 mL of growth medium under an atmosphere of nitrogen in 16 mL 
Hungate tubes shaken at 190 rpm. Conversions were determined by 1H NMR and are the 
mean of three replicate experiments. Hydrogen and formic acid were quantified after 18 h 
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using GC. b) Survival of E. coli DD-2 after 18 h reactions measured by serial dilution and 
plate count. Data shown are the mean of three independent experiments.
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Table 1
Proof-of-concept and reaction optimization experiments




1 LB + glucose no/yes PtO2, 40 mol% 15
2 M9 glucose no/yes PtO2, 40 mol% 100
3 LB + glucose yes/yes PtO2, 40 mol% 6
4 M9 glucose yes/yes PtO2, 40 mol% 91
5 LB + glucose yes/no PtO2, 40 mol% 0
6 M9 glucose yes/no PtO2, 40 mol% 15
7 M9CA glucose + Fe[c] yes/no PtO2, 20 mol% 56
8 M9CA glucose + Fe yes/no Royer, 8 mol%[d] 100
9 M9CA glucose + Fe yes/no Royer, 8 mol% 100/87[e]
Reactions were performed at a 5 mM substrate concentration in 5 mL of growth medium containing ampicillin (50 µg/mL), spectinomycin (25 µg/
mL), chloramphenicol (12.5 µg/mL), and IPTG (500 µM) under an atmosphere of either hydrogen or nitrogen in 16 mL Hungate tubes with shaking 
at 190 rpm.
[a]
E. coli strain DD-2 was used, OD600 = 0.4.
[b]
Determined by 1H NMR.
[c]
M9CA glucose + Fe medium contains Fe(NH4)2(SO4)2 (50 µM) and casamino acids (5 g/L).
[c]
Royer catalyst is 2.44 wt% palladium on polyethyleneimine/silica gel.
[d]
Reaction was performed on a 9 mmol scale (1.6 g of 1a) with 8 mol% Royer catalyst at a substrate concentration of 10 mM for 48 h (87% 
isolated yield).
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